Dishman Pharma‘s margins were down due to stock building but they are expected to pick up in the second half of this fiscal, says company MD Arpit Vyas.
first published: Nov 14, 2014 01:36 pm
A collection of the most-viewed Moneycontrol videos.
Live: Nifty reclaims 25,300, registers over 1% gain this week | Closing Bell
Live: Will Nifty bulls aim to break 25,250 after strong TCS Q2? | Opening Bell
TCS Q2 Earnings Live: Margin, Revenue Beat Street Estimates
Live: Nifty reclaims 25,100 ahead of TCS Q2 results; pharma, metals shine | Closing Bell
You are already a Moneycontrol Pro user.